Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Colorectal Neoplasms × nimotuzumab × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 4 Head and Neck Neoplasms 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Nasopharyngeal Neoplasms 2 Esophageal Neoplasms 2 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Nasopharyngeal Diseases 1 Colorectal Neoplasms 1 Carcinoma 1

Interventions

Fluorouracil 117 Leucovorin 110 Oxaliplatin 84 Bevacizumab 74 Irinotecan 66 Capecitabine 58 Cetuximab 37 Folfox protocol 30 Panitumumab 16 regorafenib 13 Drug Therapy 13 trifluridine tipiracil drug combination 12 Chemotherapy, Adjuvant 11 IFL protocol 9 Radiotherapy 8 Floxuridine 8 Neoadjuvant Therapy 7 Aspirin 7 pembrolizumab 5 XELOX 5 Mitomycin 5 Levoleucovorin 5 Laparoscopy 5 dehydroftorafur 4 atezolizumab 4 Trifluridine 4 S 1 (combination) 4 Octreotide 4 Magnetic Resonance Spectroscopy 4 Levamisole 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06343116 2024-04-02

NOTABLE-308

Biotech Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡